Cancer Genome Sequencing

Chee Seng Ku, National University of Singapore, Singapore
Nasheen Naidoo, National University of Singapore, Singapore
Mikael Hartman, National University of Singapore, Singapore
Yudi Pawitan, Karolinska Institutet, Stockholm, Sweden

Published online: December 2010

DOI: 10.1002/9780470015902.a0023262

The recent advances in high-throughput sequencing technologies have enabled several whole cancer genomes to be sequenced. In addition, a number of large-scale targeted resequencing studies have also been performed previously using Sanger sequencing methods. These studies have identified numerous somatic mutations in cancer genomes and provided new insights into the patterns of mutations in different cancer types. Several challenges remain in cancer genome sequencing such as accurately detecting different types of somatic mutations, the difficulty in identifying driver mutations, bioinformatics and analytical challenges in analysing the sequencing data and the cost of whole genome resequencing restricting the studies to a few genomes. However, cancer genome sequencing will eventually emerge as a routine tool to dissect the cancer genomes especially with the arrival of third generation sequencing technologies. The cancer genome resequencing studies have so far produced encouraging results to stimulate further studies to sequence more cancer genomes. These studies have made a significant contribution to the understanding of the somatic mutational profile of various cancers.

Key Concepts:

  • The genetic alterations of cancer occurring at the DNA sequence level can be classified as germline or somatic.
  • Somatic mutations can occur in the cancer genome in several different forms such as single and double nucleotide variants or base substitutions, small insertion–deletions (indels) and larger structural chromosomal alterations.
  • The recent advances in dissecting the somatic mutational profile of cancer genomes have been driven by high-throughput or next-generation sequencing (NGS) technologies which have enabled several whole cancer genomes to be sequenced for the first time.
  • The involvement of somatic mutations in cancer initiation and progression, in addition to germline variations, is well recognised.
  • Cancer genomes are characterised by their genomic instability which results in the occurrence of numerous somatic mutations which has proved challenging to investigate.
  • Although a large number of somatic mutations have been detected in cancer genomes, only a small subset is predicted to be ‘driver’ mutations and the remainder considered ‘passenger’ mutations.
  • Driver mutations are the mutations that initiate and drive oncogenesis steps, such as cell proliferation, tumour growth, angiogenesis, tissue invasion and metastasis.
  • Several challenges remain in cancer genome sequencing such as to accurately detect different types of somatic mutations, the difficulty in identifying driver mutations, bioinformatics and analytical challenges and the cost for whole genome resequencing has restricted the studies to a few genomes.
  • Currently there are no major obstacles in cataloging somatic mutations in cancer genomes. The real challenge lies in data interpretation and how the data can be used to discover new drugs or molecular markers for clinical applications.
  • The ultimate goals of cancer genome sequencing are to improve the clinical management of patients and the creation of personalised medicine through the development of new therapeutic agents which are tailored to the individual based on their genetic information.

Keywords: cancer genome; somatic mutation; driver mutation; whole genome resequencing; next generation sequencing technologies

Figure 1. Challenges and future directions in cancer genome sequencing.
close
 References
    Agrawal M, Garg RJ, Cortes J and Quintás-Cardama A (2010) Tyrosine kinase inhibitors: the first decade. Current Hematologic Malignancy Reports 5: 70–80.
    Bell DW (2010) Our changing view of the genomic landscape of cancer. Journal of Pathology 220: 231–243.
    Beroukhim R, Mermel CH, Porter D et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899–905.
    Brosh R and Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nature Reviews. Cancer 9: 701–713.
    Burke BA and Carroll M (2010) BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia 24: 1105–1112.
    Calin GA and Croce CM (2006) MicroRNA signatures in human cancers. Nature Reviews. Cancer 6: 857–866.
    Campbell PJ, Stephens PJ, Pleasance ED et al. (2008) Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nature Genetics 40: 722–729.
    Dalgliesh GL, Furge K, Greenman C et al. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360–363.
    Ding L, Getz G, Wheeler DA et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069–1075.
    Esquela-Kerscher A and Slack FJ (2006) Oncomirs – microRNAs with a role in cancer. Nature Reviews. Cancer 6: 259–269.
    Greenman C, Stephens P, Smith R et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153–158.
    Gupta PK (2008) Single-molecule DNA sequencing technologies for future genomics research. Trends in Biotechnology 26: 602–611.
    Harris TJ and McCormick F (2010) The molecular pathology of cancer. Nature Reviews. Clinical Oncology 7: 251–265.
    Hawkins RD, Hon GC and Ren B (2010) Next-generation genomics: an integrative approach. Nature Reviews. Genetics 11: 476–486.
    Iacobuzio-Donahue CA (2009) Epigenetic changes in cancer. Annual Review of Pathology 4: 229–249.
    International Cancer Genome Consortium (2010) International network of cancer genome projects. Nature 464: 993–998.
    Jones S, Zhang X, Parsons DW et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801–1806.
    Kan Z, Jaiswal BS, Stinson J et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869–873.
    Koboldt DC, Ding L, Mardis ER et al. (2010) Challenges of sequencing human genomes. Briefings in Bioinformatics [Epub ahead of print].
    Lee W, Jiang Z, Liu J et al. (2010) The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465: 473–477.
    Ley TJ, Mardis ER, Ding L et al. (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456: 66–72.
    Li R, Zhu H, Ruan J et al. (2010a) D novo assembly of human genomes with massively parallel short read sequencing. Genome Research 20: 265–272.
    Li Y, Hu Y, Bolund L and Wang J (2010b) State of the art de novo assembly of human genomes from massively parallel sequencing data. Human Genomics 4: 271–277.
    Maher B (2009) Exome sequencing takes centre stage in cancer profiling. Nature 459: 146–147.
    Mamanova L, Coffey AJ, Scott CE et al. (2010) Target-enrichment strategies for next-generation sequencing. Nature Methods 7: 111–118.
    Mardis ER (2008) Next-generation DNA sequencing methods. Annual Review of Genomics and Human Genetics 9: 387–402.
    Mardis ER, Ding L, Dooling DJ et al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. New England Journal of Medicine 361: 1058–1066.
    Medvedev P, Stanciu M and Brudno M (2009) Computational methods for discovering structural variation with next-generation sequencing. Nature Methods 6: S13–20.
    Metzker ML (2010) Sequencing technologies – the next generation. Nature Reviews. Genetics 11: 31–46.
    Negrini S, Gorgoulis VG and Halazonetis TD (2010) Genomic instability – an evolving hallmark of cancer. Nature Review of Molecular Cell Biology 11: 220–228.
    Parsons DW, Jones S, Zhang X et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.
    Pleasance ED, Cheetham RK, Stephens PJ et al. (2010a) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463: 191–196.
    Pleasance ED, Stephens PJ, O'Meara S et al. (2010b) A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463: 184–190.
    Pop M and Salzberg SL (2008) Bioinformatics challenges of new sequencing technology. Trends in Genetics 24: 142–149.
    Prickett TD, Agrawal NS, Wei X et al. (2009) Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nature Genetics 41: 1127–1132.
    Ragoussis J (2009) Genotyping technologies for genetic research. Annual Review of Genomics and Human Genetics 10: 117–133.
    Sharma S, Kelly TK and Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31: 27–36.
    Simpson AJ (2009) Sequence-based advances in the definition of cancer-associated gene mutations. Current Opinion in Oncology 21: 47–52.
    Sjöblom T, Jones S, Wood LD et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.
    Stephens PJ, McBride DJ, Lin ML et al. (2009) Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462: 1005–1010.
    Stratton MR, Campbell PJ and Futreal PA (2009) The cancer genome. Nature 458: 719–724.
    The ENCODE Project Consortium (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447: 799–816.
    Turner EH, Ng SB, Nickerson DA and Shendure J (2009) Methods for genomic partitioning. Annual Review of Genomics and Human Genetics 10: 263–284.
    Wang Z, Gerstein M and Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nature Reviews. Genetics 10: 57–63.
    Wood LD, Parsons DW, Jones S et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108–1113.
    Zhang X and Chang A (2007) Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. Journal of Medical Genetics 44: 166–172.
 Further Reading
    Copeland NG and Jenkins NA (2009) Deciphering the genetic landscape of cancer – from genes to pathways. Trends in Genetics 25: 455–462.
    Fox EJ, Salk JJ and Loeb LA (2009) Cancer genome sequencing – an interim analysis. Cancer Research 69: 4948–4950.
    Liu ET (2008) Functional genomics of cancer. Current Opinion in Genetics and Development 18: 251–256.
    Mardis ER (2010) Cancer genomics identifies determinants of tumor biology. Genome Biology 11: 211.
    Mardis ER and Wilson RK (2009) Cancer genome sequencing: a review. Human Molecular Genetics 18: R163–168.
    Sjoblom T (2008) Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes. Current Opinion in Oncology 20: 66–71.
    Torkamani A, Verkhivker G and Schork NJ (2009) Cancer driver mutations in protein kinase genes. Cancer Letters 281: 117–127.
    Velculescu VE (2008) Defining the blueprint of the cancer genome. Carcinogenesis 29: 1087–1091.
    Walter MJ, Graubert TA, Dipersio JF et al. (2009) Next-generation sequencing of cancer genomes: back to the future. Personalized Medicine 6: 653.
    Wooster R and Bachman KE (2010) Catalogue, cause, complexity and cure; the many uses of cancer genome sequence. Current Opinion in Genetics and Development 20: 336–341.

Related Sub-Topics:

Cancer Genetics | Gene and Genome Structure and Organisation | Techniques and Tools in Clinical Genetics
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Cancer Genome Sequencing
 
How to Cite close
Ku, Chee Seng, Naidoo, Nasheen, Hartman, Mikael, and Pawitan, Yudi(Dec 2010) Cancer Genome Sequencing. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0023262]